Table 3.

Treatment Use, Outcomes, and Adverse Effects by Treatment Group^*

	Intervention Group (n=85)	Control Group (n=81)	P-Value
Treatment Use
Treatment duration (days)
Mean (sd)	6.89 (4.55)	6.47 (4.75)	0.56
Median (IQ range)	10 (0 to 10)	10 (0 to 10)
Compliant with 10-day treatment dosing regimen (self-report) (n, %)	55/81 (68%)	51/71 (72%)	0.58
Treatment Outcomes
Change in SNOT-16 ‡ scores from Day-0 (mean, 95% CI)
Day-3	0.59 (0.47 to 0.71)	0.54 (0.41 to 0.67)	0.69
Day-7	1.06 (0.93 to 1.20)	0.86 (0.71 to 1.02)	0.0247
Day-10	1.23 (1.08 to 1.37)	1.20 (1.07 to 1.32)	0.85
Self-reported significant improvement in symptoms since Day 0 (n, %)
Day-3	37% (27% to 48%)	34% (23% to 45%)	0.67
Day-7	74% (64% to 83%)	56% (45% to 67%)	0.0205
Self-reported significant improvement in symptoms since Day 0 (n, %) (cont)
Day-10	78% (69% to 87%)	80% (71% to 90%)	0.71
Days missed from work (mean, 95% CI)	0.55 (0.28 to 0.82)	0.55 (0.22 to 0.87)	0.99
Days unable to do usual non-work activities (mean, 95%CI)	1.15 (0.76 to 1.54)	1.67 (1.08 to 2.26)	0.14
Relapse rate (%, 95%CI)	9% (3% to 16%)	6% (1% to 11%)	0.57
Recurrence rate (%, 95%CI)	6% (1% to 11%)	2% (0 to 6%)	0.44
Satisfaction with treatment (%, 95%CI)	53% (42% to 64%)	41% (29% to 52%)	0.13
Treatment Adverse Effects
Reported any side effects (%, 95%CI)	16% (8% to 24%)	14% (6% to 22%)	0.74
Responded “yes” to ≥1 specific symptom question (%, 95%CI)	48% (37% to 59%)	52% (39% to 62%)	0.75

Abbreviations: IQ range, Interquartile (25% to 75%) range; sd, standard deviation

^*The reported P-value refers to the comparison among the 2 treatment groups. The denominator is given if it is other than the total number of patients in the treatment group.

^‡The SNOT-16 score is the mean of the 16 sinusitis symptom (0=no symptoms, 3=symptoms are a large problem).